{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T20:47:16Z","timestamp":1777495636433,"version":"3.51.4"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,29]]},"DOI":"10.7759\/cureus.59298","type":"journal-article","created":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T18:13:30Z","timestamp":1714414410000},"source":"Crossref","is-referenced-by-count":2,"title":["Effectiveness of Anticoagulants in Reducing Stroke Risk Among Patients With Atrial Fibrillation"],"prefix":"10.7759","author":[{"given":"Sai Namrata","family":"Dasari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sai T","family":"Gadde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pravallika","family":"Myneni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monicaa","family":"Bodduluri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sindhu Chowdary","family":"Valiveti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/eul098","article-title":"Transcatheter ablation through the cardiac veins in a patient with a biventricular device and left ventricular epicardial arrhythmias","volume":"8","author":"Mantica M","year":"2006","unstructured":"Mantica M, De Luca L, Fagundes R, Tondo C. Transcatheter ablation through the cardiac veins in a patient with a biventricular device and left ventricular epicardial arrhythmias. Europace. 2006, 8:980-3. 10.1093\/europace\/eul098","journal-title":"Europace"},{"key":"ref2","article-title":"Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham study","volume":"147","author":"Wolf PA","year":"1987","unstructured":"Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham study. Arch Intern Med. 1987, 147:1561-4.","journal-title":"Arch Intern Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ihj.2022.11.009","article-title":"Predictors of dementia amongst newly diagnosed non-valvular atrial fibrillation patients","volume":"74","author":"Batta A","year":"2022","unstructured":"Batta A, Sharma YP, Hatwal J, Panda P, Kumar BG, Bhogal S. Predictors of dementia amongst newly diagnosed non-valvular atrial fibrillation patients. Indian Heart J. 2022, 74:505-9. 10.1016\/j.ihj.2022.11.009","journal-title":"Indian Heart J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.943239","article-title":"Bibliometric insights into the evolution of atrial fibrillation and dementia research 2002-2022","volume":"30","author":"Zhao Y","year":"2024","unstructured":"Zhao Y, Wang D. Bibliometric insights into the evolution of atrial fibrillation and dementia research 2002-2022. Med Sci Monit. 2024, 30:e943239. 10.12659\/MSM.943239","journal-title":"Med Sci Monit"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ihj.2021.12.010","article-title":"Angiographic profile and outcomes in persistent non-valvular atrial fibrillation: a study from tertiary care center in North India","volume":"74","author":"Sharma YP","year":"2022","unstructured":"Sharma YP, Batta A, Makkar K, et al.. Angiographic profile and outcomes in persistent non-valvular atrial fibrillation: a study from tertiary care center in North India. Indian Heart J. 2022, 74:7-12. 10.1016\/j.ihj.2021.12.010","journal-title":"Indian Heart J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1017\/s0317167100030390","article-title":"Is atrial fibrillation an independent risk factor for stroke?","volume":"17","author":"Phillips SJ","year":"1990","unstructured":"Phillips SJ. Is atrial fibrillation an independent risk factor for stroke?. Can J Neurol Sci. 1990, 17:163-9. 10.1017\/s0317167100030390","journal-title":"Can J Neurol Sci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199011293232209","article-title":"Atrial fibrillation-risk marker for stroke","volume":"323","author":"Chesebro JH","year":"1990","unstructured":"Chesebro JH, Fuster V, Halperin JL. Atrial fibrillation-risk marker for stroke. N Engl J Med. 1990, 323:1556-8. 10.1056\/NEJM199011293232209","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.18.2370","article-title":"Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study","volume":"285","author":"Go AS","year":"2001","unstructured":"Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. JAMA. 2001, 285:2370-5. 10.1001\/jama.285.18.2370","journal-title":"JAMA"},{"key":"ref9","article-title":"Assessment and comparison of CHADS2, CHA2DS2-VASc, and HAS-BLED scores in patients with atrial fibrillation in Saudi Arabia","volume":"11","author":"Al-Turaiki AM","year":"2016","unstructured":"Al-Turaiki AM, Al-Ammari MA, Al-Harbi SA, et al.. Assessment and comparison of CHADS2, CHA2DS2-VASc, and HAS-BLED scores in patients with atrial fibrillation in Saudi Arabia. Ann Thorac Med. 2016, 11:146-50.","journal-title":"Ann Thorac Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12114","article-title":"Atrial fibrillation prevalence revisited","volume":"274","author":"Friberg L","year":"2013","unstructured":"Friberg L, Bergfeldt L. Atrial fibrillation prevalence revisited. J Intern Med. 2013, 274:461-8. 10.1111\/joim.12114","journal-title":"J Intern Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2012-303472","article-title":"The use of anticoagulants in the management of atrial fibrillation among general practices in England","volume":"99","author":"Cowan C","year":"2013","unstructured":"Cowan C, Healicon R, Robson I, et al.. The use of anticoagulants in the management of atrial fibrillation among general practices in England. Heart. 2013, 99:1166-72. 10.1136\/heartjnl-2012-303472","journal-title":"Heart"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.595140","article-title":"Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence","volume":"114","author":"Miyasaka Y","year":"2006","unstructured":"Miyasaka Y, Barnes ME, Gersh BJ, et al.. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006, 114:119-25. 10.1161\/CIRCULATIONAHA.105.595140","journal-title":"Circulation"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1067\/mhj.2002.120410","article-title":"Recent trends in the incidence rates of and death rates from atrial fibrillation complicating initial acute myocardial infarction: a community-wide perspective","volume":"143","author":"Goldberg RJ","year":"2002","unstructured":"Goldberg RJ, Yarzebski J, Lessard D, Wu J, Gore JM. Recent trends in the incidence rates of and death rates from atrial fibrillation complicating initial acute myocardial infarction: a community-wide perspective. Am Heart J. 2002, 143:519-27. 10.1067\/mhj.2002.120410","journal-title":"Am Heart J"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/s0735-1097(96)00358-0","article-title":"Improving survival for patients with atrial fibrillation and advanced heart failure","volume":"28","author":"Stevenson WG","year":"1996","unstructured":"Stevenson WG, Stevenson LW, Middlekauff HR, et al.. Improving survival for patients with atrial fibrillation and advanced heart failure. J Am Coll Cardiol. 1996, 28:1458-63. 10.1016\/s0735-1097(96)00358-0","journal-title":"J Am Coll Cardiol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2004.08.024","article-title":"Trends in incidence and mortality in the hospital diagnosis of atrial fibrillation or flutter in Denmark, 1980-1999","volume":"103","author":"Frost L","year":"2005","unstructured":"Frost L, Vestergaard P, Mosekilde L, Mortensen LS. Trends in incidence and mortality in the hospital diagnosis of atrial fibrillation or flutter in Denmark, 1980-1999. Int J Cardiol. 2005, 103:78-84. 10.1016\/j.ijcard.2004.08.024","journal-title":"Int J Cardiol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2015.05.045","article-title":"Economic burden of undiagnosed nonvalvular atrial fibrillation in the United States","volume":"116","author":"Turakhia MP","year":"2015","unstructured":"Turakhia MP, Shafrin J, Bognar K, et al.. Economic burden of undiagnosed nonvalvular atrial fibrillation in the United States. Am J Cardiol. 2015, 116:733-9. 10.1016\/j.amjcard.2015.05.045","journal-title":"Am J Cardiol"},{"key":"ref17","article-title":"Twenty most frequent DRG groups among Medicare inpatients age 65 or older in Connecticut hospitals, fiscal years 1991, 1992, and 1993","volume":"59","author":"Hennen J","year":"1995","unstructured":"Hennen J, Krumholz HM, Radford MJ. Twenty most frequent DRG groups among Medicare inpatients age 65 or older in Connecticut hospitals, fiscal years 1991, 1992, and 1993. Conn Med. 1995, 59:11-5.","journal-title":"Conn Med"},{"key":"ref18","doi-asserted-by":"crossref","DOI":"10.1001\/archinte.1995.00430050045005","article-title":"Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications","volume":"155","author":"Feinberg WM","year":"1995","unstructured":"Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med. 1995, 155:469-73.","journal-title":"Arch Intern Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1161\/01.str.27.10.1760","article-title":"Stroke severity in atrial fibrillation. The Framingham study","volume":"27","author":"Lin HJ","year":"1996","unstructured":"Lin HJ, Wolf PA, Kelly-Hayes M, Beiser AS, Kase CS, Benjamin EJ, D'Agostino RB. Stroke severity in atrial fibrillation. The Framingham study. Stroke. 1996, 27:1760-4. 10.1161\/01.str.27.10.1760","journal-title":"Stroke"},{"key":"ref20","doi-asserted-by":"crossref","DOI":"10.1016\/0140-6736(93)92358-Z","article-title":"European atrial fibrillation trial: secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke","volume":"342","author":"EAFT (European Atrial Fibrillation Trial) Study Group","year":"1993","unstructured":"EAFT (European Atrial Fibrillation Trial) Study Group. European atrial fibrillation trial: secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet. 1993, 342:1255-62.","journal-title":"Lancet"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1161\/01.str.27.10.1765","article-title":"Acute stroke with atrial fibrillation. The Copenhagen stroke study","volume":"27","author":"J\u00f8rgensen HS","year":"1996","unstructured":"J\u00f8rgensen HS, Nakayama H, Reith J, Raaschou HO, Olsen TS. Acute stroke with atrial fibrillation. The Copenhagen stroke study. Stroke. 1996, 27:1765-9. 10.1161\/01.str.27.10.1765","journal-title":"Stroke"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart RG","year":"2007","unstructured":"Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007, 146:857-67. 10.7326\/0003-4819-146-12-200706190-00007","journal-title":"Ann Intern Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2014.03.023","article-title":"Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration","volume":"167","author":"Shore S","year":"2014","unstructured":"Shore S, Carey EP, Turakhia MP, et al.. Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration. Am Heart J. 2014, 167:810-7. 10.1016\/j.ahj.2014.03.023","journal-title":"Am Heart J"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1378\/chest.108.4_supplement.352s","article-title":"Antithrombotic therapy in atrial fibrillation","volume":"108","author":"Laupacis A","year":"1995","unstructured":"Laupacis A, Albers G, Dalen J, Dunn M, Feinberg W, Jacobson A. Antithrombotic therapy in atrial fibrillation. Chest. 1995, 108:352S-9S. 10.1378\/chest.108.4_supplement.352s","journal-title":"Chest"},{"key":"ref25","article-title":"Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation","volume":"274","author":"Gage BF","year":"1995","unstructured":"Gage BF, Cardinalli AB, Albers GW, Owens DK. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA. 1995, 274:1839-45.","journal-title":"JAMA"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-121-1-199407010-00008","article-title":"Medical treatment for stroke prevention","volume":"121","author":"Matchar DB","year":"1994","unstructured":"Matchar DB, McCrory DC, Barnett HJ, Feussner JR. Medical treatment for stroke prevention. Ann Intern Med. 1994, 121:41-53. 10.7326\/0003-4819-121-1-199407010-00008","journal-title":"Ann Intern Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger CB","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ, et al.. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011, 365:981-92. 10.1056\/NEJMoa1107039","journal-title":"N Engl J Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel MR","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, et al.. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011, 365:883-91. 10.1056\/NEJMoa1009638","journal-title":"N Engl J Med"},{"key":"ref29","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomized trials","author":"Ruff CT","year":"2014","unstructured":"Ruff CT, Giugliano RP, Braunwald E, et al.. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomized trials. Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet].  Centre for Reviews and Dissemination, York (UK); 2014. 383:955."},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.768986","article-title":"Medication adherence: its importance in cardiovascular outcomes","volume":"119","author":"Ho PM","year":"2009","unstructured":"Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009, 119:3028-35. 10.1161\/CIRCULATIONAHA.108.768986","journal-title":"Circulation"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1996.00440040081009","article-title":"Bleeding during antithrombotic therapy in patients with atrial fibrillation","volume":"156","year":"1996","unstructured":"Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med. 1996, 156.409-16. 10.1001\/archinte.1996.00440040081009","journal-title":"Arch Intern Med"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1378\/chest.119.1_suppl.8s","article-title":"Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range","volume":"119","author":"Hirsh J","year":"2001","unstructured":"Hirsh J, Dalen J, Anderson DR, Poller L, Bussey H, Ansell J, Deykin D. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 2001, 119:8S-21S. 10.1378\/chest.119.1_suppl.8s","journal-title":"Chest"},{"key":"ref33","article-title":"The stroke prevention in atrial fibrillation III study: rationale, design, and patient features","volume":"6","year":"1997","unstructured":"The stroke prevention in atrial fibrillation III study. rationale, design, and patient features. J Stroke Cerebrovasc Dis. 1997, 6:341-53.","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/s0735-1097(03)00255-9","article-title":"Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: SPORTIF II: a dose-guiding, tolerability, and safety study","volume":"41","author":"Petersen P","year":"2003","unstructured":"Petersen P, Grind M, Adler J, et al.. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: SPORTIF II: a dose-guiding, tolerability, and safety study. J Am Coll Cardiol. 2003, 41:1445-51. 10.1016\/s0735-1097(03)00255-9","journal-title":"J Am Coll Cardiol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000115528.53718.1B","article-title":"Ximelagatran or warfarin for stroke prevention in patients with atrial fibrillation?","volume":"35","author":"Hankey GJ","year":"2004","unstructured":"Hankey GJ, Klijn CJ, Eikelboom JW. Ximelagatran or warfarin for stroke prevention in patients with atrial fibrillation?. Stroke. 2004, 35:389-91. 10.1161\/01.STR.0000115528.53718.1B","journal-title":"Stroke"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.003074","article-title":"Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation","volume":"5","author":"Yao X","year":"2016","unstructured":"Yao X, Abraham NS, Alexander GC, et al.. Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation. J Am Heart Assoc. 2016, 5:e003074. 10.1161\/JAHA.115.003074","journal-title":"J Am Heart Assoc"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1161\/01.str.28.12.2382","article-title":"Warfarin use among patients with atrial fibrillation","volume":"28","author":"Brass LM","year":"1997","unstructured":"Brass LM, Krumholz HM, Scinto JM, Radford M. Warfarin use among patients with atrial fibrillation. Stroke. 1997, 28:2382-9. 10.1161\/01.str.28.12.2382","journal-title":"Stroke"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-017-0671-6","article-title":"Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration","volume":"17","author":"Borne RT","year":"2017","unstructured":"Borne RT, O'Donnell C, Turakhia MP, et al.. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration. BMC Cardiovasc Disord. 2017, 17:236. 10.1186\/s12872-017-0671-6","journal-title":"BMC Cardiovasc Disord"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.7.967","article-title":"Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities","volume":"160","author":"Samsa GP","year":"2000","unstructured":"Samsa GP, Matchar DB, Goldstein LB, Bonito AJ, Lux LJ, Witter DM, Bian J. Quality of anticoagulation management among patients with atrial fibrillation: results of a review of medical records from 2 communities. Arch Intern Med. 2000, 160:967-73. 10.1001\/archinte.160.7.967","journal-title":"Arch Intern Med"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(03)14841-6","article-title":"Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation SPORTIF III: randomised controlled trial","volume":"362","author":"Olsson SB","year":"2003","unstructured":"Olsson SB. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation SPORTIF III: randomised controlled trial. Lancet. 2003, 362:1691-1698. 10.1016\/s0140-6736(03)14841-6","journal-title":"Lancet"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.6.690","article-title":"Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial","volume":"293","author":"Albers GW","year":"2005","unstructured":"Albers GW, Diener HC, Frison L, et al.. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA. 2005, 293:690-8. 10.1001\/jama.293.6.690","journal-title":"JAMA"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2005.53215.x","article-title":"People aged over 75 in atrial fibrillation on warfarin: the rate of major hemorrhage and stroke in more than 500 patient-years of follow-up","volume":"53","author":"Johnson CE","year":"2005","unstructured":"Johnson CE, Lim WK, Workman BS. People aged over 75 in atrial fibrillation on warfarin: the rate of major hemorrhage and stroke in more than 500 patient-years of follow-up. J Am Geriatr Soc. 2005, 53:655-9. 10.1111\/j.1532-5415.2005.53215.x","journal-title":"J Am Geriatr Soc"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjopharm.2009.06.002","article-title":"Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and\/or early-stage dementia: a single-center, retrospective, observational study","volume":"7","author":"Jacobs LG","year":"2009","unstructured":"Jacobs LG, Billett HH, Freeman K, Dinglas C, Jumaquio L. Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and\/or early-stage dementia: a single-center, retrospective, observational study. Am J Geriatr Pharmacother. 2009, 7:159-66. 10.1016\/j.amjopharm.2009.06.002","journal-title":"Am J Geriatr Pharmacother"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.02.549","article-title":"Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE trial (apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation): predictors, characteristics, and clinical outcomes","volume":"63","author":"Hylek EM","year":"2014","unstructured":"Hylek EM, Held C, Alexander JH, et al.. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE trial (apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation): predictors, characteristics, and clinical outcomes. J Am Coll Cardiol. 2014, 63:2141-7. 10.1016\/j.jacc.2014.02.549","journal-title":"J Am Coll Cardiol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.1.55","article-title":"National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation","volume":"164","author":"Fang MC","year":"2004","unstructured":"Fang MC, Stafford RS, Ruskin JN, Singer DE. National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation. Arch Intern Med. 2004, 164:55-60. 10.1001\/archinte.164.1.55","journal-title":"Arch Intern Med"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1161\/circ.148.suppl_1.14464","article-title":"Abstract 14464: meta-analysis comparing early vs delayed anticoagulation after stroke in patients with atrial fibrillation","volume":"148","author":"Singh S","year":"2023","unstructured":"Singh S, Udaya Tantry, Ashley WW, Goel S, Bliden K, Gurbel P. Abstract 14464: meta-analysis comparing early vs delayed anticoagulation after stroke in patients with atrial fibrillation. Circulation. 2023, 148:10. 10.1161\/circ.148.suppl_1.14464","journal-title":"Circulation"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2310234","article-title":"Apixaban for stroke prevention in subclinical atrial fibrillation","volume":"390","author":"Healey JS","year":"2024","unstructured":"Healey JS, Lopes RD, Granger CB, et al.. Apixaban for stroke prevention in subclinical atrial fibrillation. N Engl J Med. 2024, 390:107-17. 10.1056\/NEJMoa2310234","journal-title":"N Engl J Med"},{"key":"ref48","doi-asserted-by":"crossref","DOI":"10.1001\/archinte.1995.00430030071008","article-title":"Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly","volume":"155","author":"McCrory DC","year":"1995","unstructured":"McCrory DC, Matchar DB, Samsa G, Sanders LL, Pritchett EL. Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly. Arch Intern Med. 1995, 155:277-81.","journal-title":"Arch Intern Med"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2003.023325","article-title":"Warfarin for non-rheumatic atrial fibrillation: five year experience in a district general hospital","volume":"90","author":"Yousef ZR","year":"2004","unstructured":"Yousef ZR, Tandy SC, Tudor V, Jishi F, Trent RJ, Watson DK, Cowell RP. Warfarin for non-rheumatic atrial fibrillation: five year experience in a district general hospital. Heart. 2004, 90:1259-62. 10.1136\/hrt.2003.023325","journal-title":"Heart"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1007\/s12288-014-0415-z","article-title":"Lacunae in patient knowledge about oral anticoagulant treatment: results of a questionnaire survey","volume":"31","author":"Joshua JK","year":"2015","unstructured":"Joshua JK, Kakkar N. Lacunae in patient knowledge about oral anticoagulant treatment: results of a questionnaire survey. Indian J Hematol Blood Transfus. 2015, 31:275-80. 10.1007\/s12288-014-0415-z","journal-title":"Indian J Hematol Blood Transfus"},{"key":"ref51","doi-asserted-by":"crossref","DOI":"10.1001\/archinte.1996.00440210063007","article-title":"Regional attitudes of generalists, specialists, and subspecialists about management of atrial fibrillation","volume":"156","author":"Brodsky MA","year":"1996","unstructured":"Brodsky MA, Chun JG, Podrid PJ, Douban S, Allen BJ, Cygan R. Regional attitudes of generalists, specialists, and subspecialists about management of atrial fibrillation. Arch Intern Med. 1996, 156:2553-62.","journal-title":"Arch Intern Med"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(02)11469-3","article-title":"Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial","volume":"360","author":"Eriksson BI","year":"2002","unstructured":"Eriksson BI, Bergqvist D, K\u00e4lebo P, et al.. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet. 2002, 360:1441-7. 10.1016\/s0140-6736(02)11469-3","journal-title":"Lancet"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1046\/j.1445-5994.2001.00071.x","article-title":"Outcomes in the management of atrial fibrillation: clinical trial results can apply in practice","volume":"31","author":"Jackson SL","year":"2001","unstructured":"Jackson SL, Peterson GM, Vial JH, Daud R, Ang SY. Outcomes in the management of atrial fibrillation: clinical trial results can apply in practice. Intern Med J. 2001, 31:329-36. 10.1046\/j.1445-5994.2001.00071.x","journal-title":"Intern Med J"},{"key":"ref54","article-title":"Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials","volume":"154","year":"1994","unstructured":"Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994, 154.1449-57.","journal-title":"Arch Intern Med"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.320.7244.1236","article-title":"Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness","volume":"320","author":"Kalra L","year":"2000","unstructured":"Kalra L, Yu G, Perez I, Lakhani A, Donaldson N. Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in atrial fibrillation translates into clinical effectiveness. BMJ. 2000, 320:1236. 10.1136\/bmj.320.7244.1236","journal-title":"BMJ"},{"key":"ref56","article-title":"Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: stroke prevention in atrial fibrillation II study","volume":"343","year":"1994","unstructured":"Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation. stroke prevention in atrial fibrillation II study. Lancet. 1994, 343:687-91.","journal-title":"Lancet"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(07)61233-1","article-title":"Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham atrial fibrillation treatment of the aged study, BAFTA): A randomised controlled trial","volume":"370","author":"Mant J","year":"2007","unstructured":"Mant J, Hobbs FD, Fletcher K, et al.. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham atrial fibrillation treatment of the aged study, BAFTA): A randomised controlled trial. Lancet. 2007, 370:493-503. 10.1016\/s0140-6736(07)61233-1","journal-title":"Lancet"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(89)91200-2","article-title":"Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study","volume":"333","author":"Petersen P","year":"1989","unstructured":"Petersen P, Godtfredsen J, Boysen G, Andersen E, Andersen B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet. 1989, 333:175-9. 10.1016\/s0140-6736(89)91200-2","journal-title":"Lancet"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000153002.56324.8c","article-title":"Are cost benefits of anticoagulation for stroke prevention in atrial fibrillation underestimated?","volume":"36","author":"Miller PS","year":"2005","unstructured":"Miller PS, Andersson FL, Kalra L. Are cost benefits of anticoagulation for stroke prevention in atrial fibrillation underestimated?. Stroke. 2005, 36:360-6. 10.1161\/01.STR.0000153002.56324.8c","journal-title":"Stroke"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/249234-effectiveness-of-anticoagulants-in-reducing-stroke-risk-among-patients-with-atrial-fibrillation","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T18:13:38Z","timestamp":1714414418000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/249234-effectiveness-of-anticoagulants-in-reducing-stroke-risk-among-patients-with-atrial-fibrillation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,29]]},"references-count":59,"URL":"https:\/\/doi.org\/10.7759\/cureus.59298","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,29]]}}}